EFFECTOR Reports Results Of Phase2 KICKSTART Trial Of Tomivo

eFFECTOR Therapeutics, Inc. (EFTR) announced Thursday topline results from the primary analysis of the randomized Phase 2 KICKSTART trial which tested tomivosertib or placebo, each combined with pembrolizumab, as frontline treatment for patients with non-small cell lung cancer (NSCLC) with PD-L1 =50%.

Related Keywords

Basilea , Basel Stadt , Switzerland , United States , London , City Of , United Kingdom , , T Inc , Intel Corp , Intel , Nasdaq Stock Exchange , Basilea Pharmaceutica International Ltd , Drug Administration , London Stock Exchange , Basilea Pharmaceutica International , Zevtera Antibiotic , London Stock , Intel Foundry , Nsclc , Non Small Cell Lung Cancer , Pembrolizumab , Effector , Effector Therapeutics , Lftr , Tomivosertib , Hase 2 Kickstart Trial ,